Femasys Inc. Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023

TL;DR

<b>Femasys Inc. has filed an amendment to its 2023 annual report, providing updated information for its common stock traded on NASDAQ.</b>

AI Summary

FEMASYS INC (FEMY) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Femasys Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2023. The company's common stock, par value $0.001, is traded under the symbol FEMY on the NASDAQ Capital Market. Femasys Inc. is incorporated in Delaware and its principal executive offices are located in Suwanee, GA. The filing indicates the company is a non-accelerated filer, a smaller reporting company, and an emerging growth company. The report was filed as of April 26, 2024, with the SEC.

Why It Matters

For investors and stakeholders tracking FEMASYS INC, this filing contains several important signals. This amendment to the 10-K filing suggests potential updates or corrections to the company's previously reported financial or operational data for the fiscal year 2023. As a smaller reporting and emerging growth company, Femasys Inc. may have different disclosure requirements and flexibility compared to larger, more established corporations.

Risk Assessment

Risk Level: low — FEMASYS INC shows low risk based on this filing. The risk is low as this is an amendment to a standard annual report, indicating a procedural update rather than a significant negative event.

Analyst Insight

Monitor future filings for any substantive changes or disclosures resulting from this amendment.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported Fiscal Year)
• 2024-04-26 — Filing Date (Date of Report Submission)
• 001-40492 — Commission File Number (SEC Identifier)
• 0001339005 — Central Index Key (SEC Filer Identifier)

Key Players & Entities

• FEMASYS INC (company) — Registrant Name
• FEMY (company) — Trading Symbol
• NASDAQ Capital Market (company) — Exchange
• Delaware (company) — State of Incorporation
• Suwanee, GA (company) — Principal Executive Offices Location
• 2023-12-31 (date) — Fiscal Year End
• 2024-04-26 (date) — Filing Date
• 001-40492 (regulator) — Commission File Number

FAQ

Industry Context

Femasys Inc. operates in the medical instruments and apparatus industry, focusing on surgical and medical devices.

Regulatory Implications

The company is subject to SEC regulations for public filings, including annual reports (10-K) and amendments (10-K/A).

What Investors Should Do

1. Review the full 10-K/A filing for specific details on any amendments made.
2. Track Femasys Inc. (FEMY) for any subsequent disclosures or news related to this filing.
3. Analyze the company's classification as a smaller reporting and emerging growth company for potential implications on future reporting.

Key Dates

• 2023-12-31: Fiscal Year End — The period covered by the annual report.
• 2024-04-26: Filing Date — Date the 10-K/A amendment was submitted to the SEC.

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previously filed annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 FEMY NASDAQ Capital Market Securit

Filing Documents

• ef20027751_10ka.htm (10-K/A) — 529KB
• ef20027751_ex31-3.htm (EX-31.3) — 6KB
• ef20027751_ex31-4.htm (EX-31.4) — 7KB
• 0001140361-24-022556.txt (&nbsp;) — 780KB
• femy-20231231.xsd (EX-101.SCH) — 4KB
• femy-20231231_lab.xml (EX-101.LAB) — 29KB
• femy-20231231_pre.xml (EX-101.PRE) — 21KB
• ef20027751_10ka_htm.xml (XML) — 7KB

Executive Compensation

Executive Compensation 7 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 10 Item 13. Certain Relationships and Related Transactions, and Director Independence 12 Item 14. Principal Accounting Fees and Services 14 PART IV Item 15. Exhibits, Financial Statement Schedules 14

Signatures

Signatures 16 Table of Contents PART III Item 10. Directors, Executive Officers and Corporate Governance. Information About Our Directors and Executive Officers. Board of Directors Our Board of Directors (the "Board") currently consists of five directors and is divided into three classes, with staggered three-year terms, pursuant to our amended and restated certificate of incorporation and our amended and restated bylaws. The table below sets forth our directors as of April 25, 2024. We have also included below a summary of the business experience of each of our directors, including a discussion of the qualifications, attributes and skills that led our Board to the conclusion that each of our directors should serve as a director of Femasys. Name Age Position Director Since Class I Directors: Alistair Milnes (1)(2)(6) 50 Director June 2023 Edward Uzialko, Jr. (1)(2) 73 Director August 2005 Class II Directors: Charles Larsen (3)(4)(5)(7) 72 Chairperson October 2015 Joshua Silverman (3) 54 Director November 2023 Class III Directors: Kathy Lee-Sepsick 56 Founder, President, Chief Executive Officer and Director February 2004 (1) Member of our audit committee (2) Member of our compensation committee (3) Member of our nominating and corporate governance committee (4) Chairperson of our audit committee (5) Chairperson of our compensation committee (6) Chairperson of our nominating and corporate governance committee (7) Chairperson of the Board Alistair Milnes has served as a member of our Board since June 2023. Mr. Milnes has served as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, since January 2022 and previously served as Vice President, Human Resources and Communications from January 2021 to December 2021. Previously, he served as Strategic Advisor at Rio Tinto with a focus on transformation, people and communications from January 2020 to December 2020, and in r

Executive Compensation

Executive Compensation. Our named executive officers for 2023, which consist of our principal executive officer and the next two most highly compensated executive officers, are: Kathy Lee-Sepsick, our founder, President, Chief Executive Officer and Director; Daniel Currie, our Chief Operating Officer; and Dov Elefant, our Chief Financial Officer. 7 Table of Contents Summary Compensation Table The following table provides information concerning compensation awarded to, earned by and paid to each of our named executive officers during 2023: Name and Principal Position Year Salary ($) Bonus ($) Awards (1) ($) All other compensation (2) ($) Total ($) Kathy Lee-Sepsick 2023 500,000 270,000 214,751 34,674 1,019,425 President and Chief Executive Officer 2022 423,296 — 205,403 30,280 658,979 Daniel Currie 2023 389,000 124,480 82,265 34,674 630,419 Chief Operating Officer 2022 322,373 — 153,133 30,280 505,686 Dov Elefant (3) 2023 420,000 151,200 121,084 23,940 716,224 Chief Financial Officer 2022 335,185 — 245,855 20,535 601,575 (1) The values shown reflect the grant date fair value of the stock option awards computed in accordance with FASB ASC, Topic 718. See Note 10 to the Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 28, 2024, for a discussion on the relevant assumptions used in the calculation. (2) Consists of paid family health benefits and 401K match. (3) Mr. Elefant was employed as of February 28

View Full Filing

View this 10-K/A filing on SEC EDGAR